Pieris Pharmaceuticals Inc (PIRS)

HEALTH CARE: PHARMACEUTICALS
SIC: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH

255 STATE STREET BOSTON, MA 02109

Pieris Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing therapeutic proteins for oncology, immunological disorders and anemia. The Company's proprietary drug technology, Anticalins, is based on human proteins called lipocalins. Pieris has a pipeline of Anticalin therapeutics.

Data as of 2020-06-27
Market Cap166.38 Million Shares Outstanding52.321 Million Avg 30-day Volume382.253 Thousand
P/E Ratio Dividend Yield EPS-0.42
Price/Sales3.263 Price cash flow ratio46.2 Price free cash flow ratio-3.0
Book Value0.95 Price to Tangible Book3.46 Alpha0.01
Short Interest Ratio % Short Interest to Float R-squared0.085062
BETA1.51378 52-week High/Low6.04 / 1.6 Stddev0.221427
View SEC Filings from PIRS instead.
Q1 2020 All Institutions Hedge Funds 1
Filers who had this stock in their top 10: 2 2 (0.13%)
13F Filers holding this stock: 95 38 (2.49%)
Aggregate 13F shares on 03/31/2020: 35.221 Million 24.083 Million
Aggregate 13F shares on 12/31/2019: 35.381 Million 23.855 Million
Percent change: -0.45% 0.95%
Funds creating new positions: 17 5
Funds Adding to an existing position: 30 16
Funds closing out their position: 19 7
Funds reducing their position: 30 12
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding PIRS (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding PIRS BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

GERAGHTY JAMES A

  • Director
91,253 2020-07-01 2

KHUONG CHAU QUANG

  • Director
3,122,770 2020-06-30 0

SAID MAYA R.

0 2020-06-25 5

PRELACK STEVEN

  • Director
0 2020-06-24 0

RICHMAN MICHAEL

0 2020-06-23 4

KIRITSY CHRISTOPHER P

0 2020-06-23 3

BARBIER ANN

0 2020-06-23 2

KIENER PETER A

0 2020-06-23 2

SHERMAN MATTHEW L

0 2020-06-23 2

BVF PARTNERS L P/IL

BIOTECHNOLOGY VALUE FUND L P

BIOTECHNOLOGY VALUE FUND II LP

BIOTECHNOLOGY VALUE TRADING FUND OS LP

BVF PARTNERS OS LTD.

BVF INC/IL

LAMPERT MARK N

  • 10% Owner
  • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
480,432 2020-05-21 2

BIZZARI JEAN-PIERRE

  • Director
82,314 2020-04-30 1

AQUILO CAPITAL MANAGEMENT, LLC

  • 10% Owner
5,575,530 2020-03-12 1

YODER STEPHEN S. CHIEF EXECUTIVE OFFICER

0 2020-02-27 1

KAUFMANN HITTO SVP, CHIEF SCIENTIFIC OFFICER

0 2020-02-27 3

BURES THOMAS VICE PRESIDENT, FINANCE

0 2020-02-27 2

MATIS LOUIS CHIEF DEVELOPMENT OFFICER

0 2019-02-26 0

REINE ALLAN CHIEF FINANCIAL OFFICER

0 2019-02-26 0

ORBIMED ADVISORS LLC

ORBIMED CAPITAL GP III LLC

  • 10% Owner
14,915,535 2018-08-16 0

ADAMS JULIAN

  • Director
0 2018-06-26 0

ORBIMED ADVISORS LLC

ORBIMED CAPITAL GP III LLC

ISALY SAMUEL D

  • 10% Owner
5,550,000 2018-01-03 0

DEPTULA-HICKS DARLENE M

  • Director
No longer subject to file 2017-08-09 0

THIBAULT LANCE E ACTING CHIEF FINANCIAL OFFICER

  • Officer
0 2017-02-02 0

KNOPF CLAUDE CHIEF BUSINESS OFFICER

  • Officer
0 2016-11-28 0

TAKKE CHRISTINA

  • Director
0 2015-06-29 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

SAID MAYA R.

2020-06-25 A 40,000 a 40,000 0.00 direct

KIRITSY CHRISTOPHER P

2020-06-23 A 40,000 a 40,000 0.00 direct

GERAGHTY JAMES A

2020-06-23 A 45,000 a 45,000 0.00 direct

RICHMAN MICHAEL

2020-06-23 A 40,000 a 40,000 0.00 direct

BARBIER ANN

2020-06-23 A 40,000 a 40,000 0.00 direct

KIENER PETER A

2020-06-23 A 40,000 a 40,000 0.00 direct

SHERMAN MATTHEW L

2020-06-23 A 40,000 a 40,000 0.00 direct

SAID MAYA R.

2020-06-23 A 40,000 a 40,000 0.00 direct

KIRITSY CHRISTOPHER P

2020-06-23 A 40,000 a 40,000 0.00 direct
Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments